Sign In
Buy HTBX
$2.38
+0 (+0%)
At Close: Aug 17, 2022
Genprex Added to Russell 3000® Index
12:00am, Monday, 29'th Jun 2020
Genprex is added to the Russell 3000 Index
AnHeart Therapeutics Announces Acceptance of Taletrectinib Phase 1 Data for Publication in Clinical Cancer Research
02:01pm, Friday, 26'th Jun 2020Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm
12:00am, Friday, 26'th Jun 2020
uPath PD-L1 (SP263) image analysis uses automated pre-computing and one-click scoring to enable quicker and accurate detection and measurement of tumour...
BeyondSpring : 2020 First Quarter Financial Report | MarketScreener
06:49pm, Thursday, 25'th Jun 2020Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate
12:00am, Thursday, 25'th Jun 2020
Genprex receives USAN Adoption of Generic Drug Name
Genprex CEO to Interview Live on “The Big Biz Show”
12:00am, Wednesday, 24'th Jun 2020
Genprex's CEO will interview on the Big Biz Show on Thursday, June 25.
3 Reasons Jazz Pharmaceuticals Is A Hot Buy Right Now | The Motley Fool
11:06am, Tuesday, 23'rd Jun 2020
A new small-cell lung cancer drug approval isn't the only thing the company has going for it.
Bristol Myers Squibb : Supplemental epidemiology information | MarketScreener
03:27pm, Monday, 22'nd Jun 2020Why Heat Biologics Stock Is Trading Higher Today
02:54pm, Monday, 22'nd Jun 2020
Heat Biologics Inc (NASDAQ: HTBX) shares are trading higher on Monday after the company announced the first patient has been treated in its first-in-human clinical trial of PTX-35.Heat Biologics is a
Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35 | | IT Business Net
12:12pm, Monday, 22'nd Jun 2020
DURHAM, NC / ACCESSWIRE / June 22, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate t
Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35
11:30am, Monday, 22'nd Jun 2020
DURHAM, NC / ACCESSWIRE / June 22, 2020 / Heat Biologics, Inc. ("Heat") (HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system,
KEYTRUDA® Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Newsflash: Heat Biologics, Inc. (NASDAQ:HTBX) Analysts Have Been Trimming Their Revenue Forecasts
01:49pm, Saturday, 20'th Jun 2020
Market forces rained on the parade of Heat Biologics, Inc. (NASDAQ:HTBX) shareholders today, when the analysts...
